Clinical Study
Effects of Telmisartan with Hydrochlorothiazide versus Valsartan with Hydrochlorothiazide in Patients with Moderate-to-Severe Hypertension
Table 3
Adverse events with incidence ≥2%.
| | T80/H25 () | V160/H25 () | Placebo () |
| | Patients with any adverse event, n (%) | 94 (27.9) | 73 (22.3) | 37 (42.5) | | Upper respiratory tract infection, n (%) | 6 (1.8) | 5 (1.5) | 3 (3.4) | | Sinusitis, n (%) | 2 (0.6) | 4 (1.2) | 2 (2.3) | | Headache, n (%) | 8 (2.4) | 7 (2.1) | 4 (4.6) | | Dizziness, n (%) | 7 (2.1) | 7 (2.1) | 3 (3.4) | | US spelling-diarrhea n (%) | 5 (1.5) | 2 (0.6) | 3 (3.4) | | Dry mouth, n (%) | 1 (0.3) | 1 (0.3) | 2 (2.3) | | Vomiting, n (%) | — | 2 (0.6) | 2 (2.3) | | Muscle spasm, n (%) | 3 (0.9) | 5 (1.5) | 2 (2.3) | | Hypertension, n (%) | — | — | 5 (5.7) | | Fatigue, n (%) | 6 (1.8) | 2 (0.6) | 2 (2.3) |
|
|
T80/H25: telmisartan 80 mg/hydrochlorothiazide 25 mg; V160/H25: valsartan 80 mg/hydrochlorothiazide 25 mg.
|
